Applied Spectral Imaging Launches Version 7.2 of GenASIs – A New Era in Pathology and Cytogenetic Imaging

GenASIs 7.2 – The Market’s most Comprehensive Computer Aided Cytogenetic and Pathology Imaging and Analysis Platform

Carlsbad, CA. – Dec. 18, 2012 – Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today the launch of Version 7.2 of GenASIs – a comprehensive cytogenetic and pathology imaging platform.

GenASIs Version 7.2 introduces major enhancements to ASI’s offering of existing imaging applications and positions ASI as a leader in both cytogenetic and pathology imaging and analysis. The new platform offering includes unparalleled accuracy and efficiency for automated and interactive imaging applications. In addition, GenASIs Version 7.2 includes advance imaging applications from fully automated to fully interactive workflows for tissue FISH and cytogenetic FISH, Immunohistochemistry (IHC) analysis, karyotyping (including automated metaphase finding).

 “The introduction of GenASIs 7.2 is our first step in establishing ASI as a leader in automated and interactive pathology and cytogenetic imaging and analysis. We are excited to add Quantitative IHC pathology imaging and analysis, along with other important enhancements, to our flagship platform - GenASIs. This new offering is in line with our strategy to offer clinicians and researchers the most advanced, efficient and accurate instruments supporting advancements in computer-aided analysis for personalized medicine, companion diagnostics, cancer research, diagnostic and other pathology and cytogenetic applications.” said Limor Shiposh, CEO of Applied Spectral Imaging.

The launch of GenASIs Version 7.2 introduces both enhancements as well as new capabilities to the GenASIs imaging and analysis platform. These enhancements include the combining fluorescent and bright-field pathology analysis with both IHC and FISH imaging and analysis in a single platform. Moreover, GenASIs introduces new levels of automation and time-savings adding Microsoft Windows 7 64bit operating system support as well as optimized workflows for fully-interactive FISH spot-counting and enhanced analysis capabilities. Other enhancements include improved laboratory information system (LIS) integration and management tools including detailed audit-trail, backup, recovery and maintenance.

“We have learnt from our customers that combining cytogenetic and pathology analysis adds real value making patient care better and more affordable. Furthermore, our customers have asked for a flexible solution suite supporting fully-automated “walk-away” as well as fully interactive imaging and analysis. We have listened to our customers and are proud to introduce the GenASIs Version 7.2 platforms including our new Go-Path quantitative IHC analysis platform” said Yagil Tzur, Program Director at Applied Spectral Imaging.

About ASI

Applied Spectral Imaging (ASI) makes patient care better through advanced biomedical imaging.

GenASIs by ASI is FDA cleared for FISH clinical applications such as UroVysion, HER2/neu, CEP XY and Karyotyping. ASI complies with major regulatory requirements and international quality standards.

ASI has been one of the industry's leading microscopy imaging solution provider since 1993, with over 30 registered patents in the US, Europe and Japan and over 2,500 systems deployed worldwide. With worldwide offices in the US, Europe and Asia, ASI has built a global network of over 50 distributors.

 

# # #

 

 

For More Information Please Contact –

For More Information Contact –

Mrs. Limor Shiposh, Chief Executive Officer

Phone: +1 (760) 929 2840

E-mail: limor@spectral-imaging.com

www.spectral-imaging.com